Literature DB >> 25666710

MicroRNA-145 contributes to enhancing radiosensitivity of cervical cancer cells.

Chen Ye1, Ning-xia Sun1, Yan Ma2, Qian Zhao1, Qing Zhang1, Chen Xu1, Shao-bing Wang3, Shu-han Sun3, Fang Wang4, Wen Li5.   

Abstract

In our study, transcriptome microarrays are used to identify differentially expressed miRNAs and mRNAs in cervical cancer specimens. We find that microRNA-145 (miR-145) expression is significantly decreased in cervical cancer tissues and cell lines, and is associated with advanced cancer stages, large tumor size and moderate/poor differentiation. We show that miR-145 targets the DNA damage repair-associated gene Helicase-like transcription factor (HLTF), which is involved in radio-resistance. Moreover, miR-145 over-expression in cervical cancer cells enhances radiosensitivity in vitro and in vivo. These results indicate that targeting miR-145 may be a novel radiosensitizing strategy for cervical cancer.
Copyright © 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Helicase-like transcription factor; MicroRNA-145; Microarray; Radiosensitivity

Mesh:

Substances:

Year:  2015        PMID: 25666710     DOI: 10.1016/j.febslet.2015.01.037

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  17 in total

Review 1.  The helicase-like transcription factor (HLTF) in cancer: loss of function or oncomorphic conversion of a tumor suppressor?

Authors:  Ludovic Dhont; Céline Mascaux; Alexandra Belayew
Journal:  Cell Mol Life Sci       Date:  2016-01       Impact factor: 9.261

2.  LINC00337 Regulates KLF5 and Maintains Stem-Cell Like Traits of Cervical Cancer Cells by Modulating miR-145.

Authors:  Qi Han; Wenjin Wu; Yulan Cui
Journal:  Front Oncol       Date:  2020-08-14       Impact factor: 6.244

3.  Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway.

Authors:  Lili Song; Shikai Liu; Sufen Zhao
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

Review 4.  MicroRNAs, DNA Damage Response, and Cancer Treatment.

Authors:  Mingyang He; Weiwei Zhou; Chuang Li; Mingxiong Guo
Journal:  Int J Mol Sci       Date:  2016-12-12       Impact factor: 5.923

5.  miR‑328‑3p enhances the radiosensitivity of osteosarcoma and regulates apoptosis and cell viability via H2AX.

Authors:  Zhen Yang; Qing-De Wa; Chao Lu; Wei Pan; Zi-Μo Lu; Jun Ao
Journal:  Oncol Rep       Date:  2017-11-27       Impact factor: 3.906

6.  Plasma miR-145 as a novel biomarker for the diagnosis and radiosensitivity prediction of human cervical cancer.

Authors:  Hu Wei; Chen Wen-Ming; Jiao Jun-Bo
Journal:  J Int Med Res       Date:  2017-05-23       Impact factor: 1.671

7.  Novel role of PAF1 in attenuating radiosensitivity in cervical cancer by inhibiting IER5 transcription.

Authors:  Jing-Jie Zheng; Yue He; Yang Liu; Feng-Shuang Li; Zhen Cui; Xiao-Meng Du; Chun-Peng Wang; Yu-Mei Wu
Journal:  Radiat Oncol       Date:  2020-05-29       Impact factor: 3.481

Review 8.  Cardiac Resynchronization Therapy Outcomes in Type 2 Diabetic Patients: Role of MicroRNA Changes.

Authors:  Celestino Sardu; Michelangela Barbieri; Maria Rosaria Rizzo; Pasquale Paolisso; Giuseppe Paolisso; Raffaele Marfella
Journal:  J Diabetes Res       Date:  2015-11-09       Impact factor: 4.011

9.  Identification of key genes associated with cervical cancer by comprehensive analysis of transcriptome microarray and methylation microarray.

Authors:  Ming-Yan Liu; Hong Zhang; Yuan-Jing Hu; Yu-Wei Chen; Xiao-Nan Zhao
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

10.  MicroRNA-199a Inhibits Cell Proliferation, Migration, and Invasion and Activates AKT/mTOR Signaling Pathway by Targeting B7-H3 in Cervical Cancer.

Authors:  Xiang Yang; Kai-Xun Feng; Hu Li; Li Wang; Hong Xia
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.